Purdue Pharma to stop marketing opioids to U.S. physicians, but policy not extended to Canada
published on February 11, 2018 by Andrea Woo in The Globe and Mail
The pharmaceutical giant that misled physicians and patients about the addictive properties of its top-selling drug OxyContin, fuelling an overdose crisis that has devastated communities across North America, will stop marketing opioids to U.S. physicians.
However, the new policy does not extend into Canada.
Purdue Pharma L.P. announced the change in a statement issued on the weekend.
The company has sent notices to U.S. health-care providers saying its sales representatives will “no longer be visiting your office to engage you in discussions about our opioid products” effective Monday.
Keith Ahamad, an addictions physician and a clinician researcher with the BC Centre on Substance Use, said it’s too late for the new directive to have any meaningful impact.View the full article